美股異動|邁威爾科技盤前大跌超16% 首財季營收指引遜於華爾街最高預期
芯片製造商邁威爾科技(MRVL.US)盤前大跌16.45%,報75.31美元。消息面上,邁威爾科技公佈截至2月1日止第四財季業績,營收同比增加20%至18.2億美元,高於分析師預期的18億美元;期內扭虧錄得淨利潤2億美元,經調整每股盈利爲0.6美元,分析師預期爲0.59美元。然而,該公司公佈了審慎的首財季展望,預計營收爲18.8億美元(上下浮動5%),分析師平均預期爲18.7億美元,但部分預期高達20億美元;調整後每股盈利爲0.61美元(上下浮動0.05美元),分析師預期爲0.6美元。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.